Johnson & Johnson (JNJ) Asset Writedowns and Impairment (2009 - 2026)

Johnson & Johnson (JNJ) has 18 years of Asset Writedowns and Impairment data on file, last reported at -$8.0 million in Q1 2026.

• Quarterly Asset Writedowns and Impairment fell 100.0% year-over-year to -$8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (down 50.12% YoY) and the FY2025 annual result came in at $204.0 million, down 49.63% from the prior year.
• Asset Writedowns and Impairment fell to -$8.0 million in Q1 2026 per JNJ's latest filing, from $81.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $820.0 million in Q4 2023, with the low at -$981.0 million in Q1 2023.
• Average Asset Writedowns and Impairment over 5 years is $117.3 million, with a median of $81.0 million recorded in 2025.
• Year-over-year, Asset Writedowns and Impairment soared 4792.31% in 2022 and sank 100.0% in 2026.
• Johnson & Johnson's Asset Writedowns and Impairment stood at $610.0 million in 2022, then fell by 22.13% to $475.0 million in 2023, then tumbled by 94.53% to $26.0 million in 2024, then jumped by 211.54% to $81.0 million in 2025, then tumbled by 109.88% to -$8.0 million in 2026.
• Business Quant data shows JNJ's Asset Writedowns and Impairment at -$8.0 million in Q1 2026, $81.0 million in Q4 2025, and $93.0 million in Q3 2025.